Cocarnit in female patients with ischemic placental disease in the postpartum period

Abstract

Yu.E. Dobrokhotova, L.S. Dzhokhadze Pirogov Russian National Research Medical University, Moscow, Russian Federation Ischemic placental disease, which includes such nosological entities as preeclampsia, fetal growth retardation and placental abruption, is commonly the cause of premature labor, which makes it an urgent medical and biological problem. To increase the efficacy of preventive measures, it seems promising to use metabolic therapy, which implies a direct effect on metabolic processes at the tissue and cellular levels. The antioxidant effect of metabolic drugs can reduce the formation of reactive oxygen species and peroxyl radicals in the blood and tissues, and prevent cellular damage. The authors present their experience concerning the use of Cocarnit® metabolic drug, which includes triphosadenine, cocarboxylase, cyanocobalamin and nicotinamide, in complex therapy in the late postpartum period in patients with ischemic placental disease. The use of this drug improves the hemodynamic parameter control, normalizes carbohydrate metabolism, contributes to the rapid restoration of hemoglobin levels in combination with iron preparations, as well as to a softer and faster rehabilitation of female patients in this group, increasing the probability of a favorable outcome in future pregnancy. It should be noted that the preliminary results obtained by the authors require further randomized comparative clinical trials on large samples. Keywords: pregnancy, ischemic placental disease, postpartum period, fetal death, Cocarnit, triphosadenine, cocarboxylase, nicotinamide, cyanocobalamin, metabolic therapy. For citation: Dobrokhotova Yu.E., Dzhokhadze L.S. Cocarnit in female patients with ischemic placental disease in the postpartum period. Russian Journal of Woman and Child Health. 2023;6(4):385–390 (in Russ.). DOI: 10.32364/2618-8430-2023-6-4-10.